Market Research Logo

Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

Report Scope:

The scope of this study is clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical research segment, currently approved CTC tests and their markets. The regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share along with the latest trends and new developments in this area are included to support the clinical testing market.

The research segment of the market includes numerous competitors with different capabilities, developing and commercializing products such as CTC isolation devices and protocols, CTC characterization reagents, assay and instrumentation, and various identification technologies based on cell imaging. These market players include specialized or research-based companies that contribute considerably to the technological advancements in the field of CTC technologies.

The data collected for the report is focused on breast, prostate and colorectal cancers for which clinical data and tests are available currently on the market. CTCs in other cancers are being researched and some are in clinical trials; these are not included within the scope of this report.

Report Includes:

- 118 Tables
- An overview of the global market for cancer diagnostics, based on circulating tumor cells, which are used to increase understanding of tumor cell biology and metastatic cancer as a disease.
- Analyses of global market trends, with data from 2016, estimates from 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Discussions covering the advantages and disadvantages of CTC enrichment techniques.
- Estimations of cancer incidence, cancer deaths, new cases by type in the United States, and breast cancer statistics and facts.
- Examination of growth opportunities and drivers in the CTC market and recent breakthroughs in research, along with a patent analysis.
- Information about the clinical testing, prognostic, and monitoring markets for CTCs in cancer.
- Coverage of approved CTC tests and their markets, and the regulatory environment.
- Company profiles of major players across various product categories, including Cytotrack, Menarini-Silicon Biosystems And A. Menarini Diagnostics (Veridex Llc), Greiner Bio-One Gmbh, Cynvenio Biosystems Inc., Biofluidica Microtechnologies Llc and Advanced Cell Diagnostics


Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Intended Audience
Scope of the Study
Methodology
Information Sources
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Circulating Tumor Cells
Cancer
Recent Advances in Technology
Invasive Power
Circulating Tumor Cells
Phenotypic Characteristics
CTC Clusters
CTC Detection
Cancer Stem Cells (CSCs)
Circulating Tumor Cells- Potential Uses
Proliferative Activity
Epithelial Marker Genes on Circulating Tumor Cells
Circulating Tumor Cells and Stem Cell-Like Phenotype
CTCs and Primary Tumor Cells: Comparison
Metastasis
Future Directions
Metastatic Development in Cancer Patients
Circulating Tumor Cell Migration
Important Markers of Distant Metastasis
Circulating Tumor Cell Detection
Methods
CellSearch Method
Epic Sciences Method
Maintrac
ISET Test
Challenges for Detection
Clinical Application of Circulating Tumor DNA
Circulating Tumor Cells as Predictor of Response to Therapy
Measurement of CTCs-Applications
Conclusion
Chapter 4 Incidence of Cancer
Worldwide Growth in the Incidence of Cancer
Causes of Cancer
Risk Factors for Cancers
Burden of Cancer
Avoiding Risk Factors
Early Detection
Treatment
Palliative Care
World Health Organization Response
World Cancer Statistics
Cancer and the Global Impact
Global Patterns
Future of Cancer
Common Types of Cancers
U.S. Cancer Incidence
Global Breast Cancer
Colorectal Cancer
Prostate Cancer
Cancer in Europe
Prostate Cancer in Asia
Other Nations
Conclusions
Chapter 5 Technologies
Finding Circulating Tumor Cells
Why CTCs?
Current CTC Detection and Isolation Methods
New Technologies for Detection
Cancer Prognosis
CTC Detection Techniques - Requirements
Nucleic Acid-based Methods
Clinical Testing
Summary
New Emerging Technologies
Chapter 6 Circulating Tumor Cells and Cancer Diagnostics
Use of CTCs for Diagnosis
Current Methods and Applications
Circulating Tumor Cells in Prostate Cancer: Case Studies
CTCs in Companion Diagnostics
Newer Technologies in Development
Molecular Analyses of CTC
Conclusions
Chapter 7 CTCs in Clinical Trials
CTC Diagnostics
Circulating Tumor Cell Technology
Potential Therapeutic Uses of Circulating Tumor Cells
Challenges in the Detection of Circulating Tumor Cells
CTCs as Clinical Biomarkers
PCR-based Markers
Circulating Tumor Cells in Cancer -Current Status
Prognostic and Predictive Value of CTCs
CTCs in Clinical Cancer Management
Existing Technologies in Clinical Trials
Clinical Studies Using CellSearch Technology
Approvals
Recent Studies
Possible Use of CTCs and DTCs as New Biomarkers
Clinical Applications
Application of CTC Technologies to Clinical Testing
CTC Technologies for Clinical Development
Standard Recommendations
CTC Number as a Prognostic Biomarker
Prognostic Studies
CTCs as a Surrogate Response Biomarker
CTCs as a Real-time Biopsy
CTC Chip Technology and EGFR Mutation Analysis
CTC Characterization after Enrichment Using the CellSearch Platform
Final Remarks
Chapter 8 Circulating Tumor Cell Market
Invasive Cancer
Cancer Survival
Global Annual Oncology Market
Cancer Therapy
Aging and Cancer
Cancer Drug Pipeline
Cancer Costs in the U.S.
Japan Oncology Drugs Market
Breast Cancer
Colon and Rectum
Prostate
Chemotherapy Market
Cancer Testing Market
Current Cancer Diagnostic Tests
A Universal Tumor Test-Is it Possible?
Cancer Biomarker Testing Market
Molecular Diagnostics
Cancer Biomarker Tests
Cancer Disease Management
Personalized Cancer Testing
Circulating Tumor Cell Market-A New Approach
Clinical Diagnostics Market
Current Status of the Market
Future and Next Steps
Chapter 9 Patents Overview
Key Patents
Menarini-Silicon Biosystems/Veridex
Magsweeper
Scripps Research Institute (EPIC Sciences)
CellPoint Diagnostics
University of Washington
Biofluidica
Adnagen
Filtini
Ikonisys
Aviva Biosciences
Harvard University-Mehmet Toner, PhD
Cellective Dx
Johns Hopkins University
Medical Discovery Partners
Cynvenio Biosystems
ScreenCell
Canopus Bioscience
Advanced Cell Diagnostics
Biocept
TRUECELLS
Roche Molecular Systems and the University of North Carolina
Cellectar Biosciences
The General Hospital Corp.
The Trustees of the University of Pennsylvania Patents
Epic Sciences
Immunomedics
Chapter 10 Selected Company Profiles
Companies
Key Players
Key Company Profiles
ADNAGEN
ADVANCED CELL DIAGNOSTICS
APOCELL
AVIVA BIOSCIENCES
BIOCEP LTD.
BIOCEPT INC.
BIOFLUIDICA MICROTECHNOLOGIES LLC
CANOPUS BIOSCIENCES
CELLMAX LIFE
CELLTRAFIX INC.
CELULA
CLEARBRIDGE BIOMEDICS
CREATV MICROTECH INC
CYNVENIO BIOSYSTEMS INC.
CYTOTRACK
EPIC BIOSCIENCES
FLUXION BIOSCIENCES
GREINER BIO-ONE GMBH
IKONISYS INC.
IVDIAGNOSTICS INC
JANSSEN DIAGNOSTICS
MENARINI-SILICON BIOSYSTEMS
MILTENYI BIOTEC
NANOSTRING TECHNOLOGIES INC.
NATURAL NANO INC.
RARECELLS
SCREENCELL
STEMCELL TECHNOLOGIES
SYNERGEX CORP.
SYSMEX CORP.
VITATEX INC.
List Of Tables
Summary Table : Global Circulating Tumor Cell Technology Market, by Cancer Type, Through 2022
Table 1 : Categories of Stem Cells
Table 2 : Product Categories
Table 3 : Key Success Factors of CTCs
Table 4 : Types of CTCs
Table 5 : Circulating Tumor Cells – Features
Table 6 : Metastatic Cascade
Table 7 : EPCAM-based Assays
Table 8 : CellSearch Tests
Table 9 : Liquid Biopsy Technologies
Table 10 : Cancer – Key Facts
Table 11 : Cancer Causes
Table 12 : Cancer Causing Factors
Table 13 : Cancer Screening Methods
Table 14 : Noncommunicable Diseases Action Plan
Table 15 : Global Cancer Incidence and Mortality, 2012 and 2035
Table 16 : Cancer in 2013
Table 17 : Global Cancer Statistics for the Most Common Cancers, 2012
Table 18 : Increase in Cancer Burden – Factors
Table 19 : Main Types of Cancers and Associated Mortality
Table 20 : General Global Cancer Incidence, by Type
Table 21 : Common Types of Cancers in U.S., Estimated New Cases, 2013
Table 22 : Global Breast Cancer Incidence, 2012-2022
Table 23 : Global Breast Cancer Facts
Table 24 : Breast Cancer in the U.S.
Table 25 : Breast Cancer in U.S., 2012-2022
Table 26 : Global Colorectal Cancer, 2012-2022
Table 27 : Global Colorectal Cancer Incidence (Estimated): Mortality and Prevalence, 2012
Table 28 : Colorectal Cancer Incidence Estimates in U.S., 2012-2022
Table 29 : Number of People Living with Colorectal Cancer Estimates in U.S., 2016
Table 30 : Colon and Rectal Cancer Incidence Estimates in U.S., 2013-2022
Table 31 : Incidence and Deaths for Prostate Cancer, 2013
Table 32 : Prostate Cancer Incidence and Mortality Worldwide, 2012
Table 33 : Highest Incidence of Prostate Cancer, by Country, 2012
Table 34 : Global Estimated Prostate Cancer Deaths: Age-Standardized Mortality Rates per 100,000 Men, 2012
Table 35 : Global Estimated New Cases of Prostate Cancer, 2012-2022
Table 36 : Prostate Cancer Statistics, 2016
Table 37 : Estimated New Cases and Deaths of Prostate Cancer in U.S., 2012–2016
Table 38 : Estimated Prostate Cancer Cases in U.S., 2020 and 2030
Table 39 : Prostate Cancer Statistics: New Cases and Deaths in U.S., by Race, 2007-2012
Table 40 : Prostate Cancer Stage and Survival Rate
Table 41 : Incidence Rates by Race in U.S., 2005-2009
Table 42 : Mortality Rates by Race in U.S., 2005-2009
Table 43 : Relative Survival Rate for Prostate Cancer Patients
Table 44 : Five-year Relative Survival by Stage at the Time of Diagnosis
Table 45 : Estimated Prostate Cancer in Canada, 2015
Table 46 : Estimated Prostate Cancer Mortality in EU27 Countries: Age-Standardized Mortality Rates per 100,000 Men, 2012
Table 47 : Prostate Cancer Deaths in U.K.: Rate per 100,000 People, 2014
Table 48 : Estimated Prostate Cancer Diagnosed in 2016
Table 49 : Potential Applications of CTC-based Diagnostics
Table 50 : Clinical Relevance of CTC
Table 51 : CTC Enrichment Methods
Table 52 : Techniques Used for CTC Enrichment
Table 53 : Techniques Used for CTC Analysis
Table 54 : Enumeration Techniques
Table 55 : Functional Assays
Table 56 : Circulating Tumor Cells Technologies
Table 57 : Micro-Count Features: A New Technology
Table 58 : CTC Assay Pre-Analytical Validation Considerations
Table 59 : CTC Assay Analytical Validation Considerations
Table 60 : CTC Assay Post-Analytical Validation Considerations
Table 61 : Current Enrichment Assays for CTCs
Table 62 : CTC Enumeration Assays
Table 63 : Characterization Assays for CTCs
Table 64 : Key Features of IVD CTC Tests
Table 65 : Prostate Cancer Diagnosis and Role of CTCs
Table 66 : Current Diagnostic Methods
Table 67 : ApoStream Key Features
Table 68 : Canopus Bioscience Technology – Benefits
Table 69 : CellOptics’ Cancer Application
Table 70 : CellOptics’ Key Features – Enrichment
Table 71 : CellOptics’ Key Features – Labeling
Table 72 : CellOptics’ Key Features – Detection
Table 73 : ISET Test – Specifications
Table 74 : CTC Technologies for Clinical Management
Table 75 : CTC Technologies for Clinical Management
Table 76 : CTC Assay Clinical Readiness Evaluation
Table 77 : CTC Assay Analytical Validation Considerations
Table 78 : CTC Qualification Studies
Table 79 : Global Cancer Incidence – Estimates, 2008-2030
Table 80 : Global Cancer Survivors, 2008
Table 81 : Burden of Cancer in U.S., 2016
Table 82 : U.S. Cancer Survivors, 2008–2022
Table 83 : Male Cancer Survivors
Table 84 : Female Cancer Survivors
Table 85 : Global Cancer Drug Companies
Table 86 : Global Cancer Drug Market, Through 2022
Table 87 : Drugs Approved in 2017
Table 88 : Cancer Forecast in U.S., 2020 – Key Facts
Table 89 : Cancer Care Cost in U.S., 2010 and 2020
Table 90 : Global In Vitro Diagnostics Market, Through 2022
Table 91 : Key Players
Table 92 : Significant Developments in Cancer Follow-Up
Table 93 : Cancer Tests and Limitations – the Case Against Development of a Universal Test
Table 94 : Global Cancer Biomarkers Market, Through 2022
Table 95 : Key Players
Table 96 : Global Molecular Diagnostics Market, Through 2022
Table 97 : CTCs – Differentiating Features
Table 98 : Stem Cell Market Overview
Table 99 : Key Companies Selling Stem Cell Research Products
Table 100 : CTC Companies with Promising Products
Table 101 : Clinical Use of CellSearch System
Table 102 : Estimated Pricing
Table 103 : CellSearch Kit
Table 104 : Global Circulating Tumor Cell Testing Market, by Region, Through 2022
Table 105 : Global Circulating Tumor Cells for Prostate Cancer Market, by Region, Through 2022
Table 106 : Global Circulating Tumor Cells for Breast Cancer Market, by Region, Through 2022
Table 107 : Global Circulating Tumor Cells for Colorectal Cancer Market, by Region, Through 2022
Table 108 : U.S. Circulating Tumor Cells for Prostate Cancer Market, Through 2022
Table 109 : U.S. Circulating Tumor Cells Market, by Cancer Type, Through 2022
Table 110 : European Circulating Tumor Cells Market, Through 2022
Table 111 : European Circulating Tumor Cells Market, by Cancer Type, Through 2022
Table 112 : Rest of World Circulating Tumor Cells Market, Through 2022
Table 113 : Rest of World Circulating Tumor Cells Market, by Cancer Type, Through 2022
Table 114 : Circulating Tumor Cell Assay Characteristics
Table 115 : CTC Selected Patents
Table 116 : Key Patents by Aviva Biosciences
Table 117 : Commercial Circulating Tumor Cell Technology Platforms
List Of Figures
Summary Figure : Global Circulating Tumor Cell Technology Market, by Cancer Type, 2012-2022
Figure 1 : Global Cancer Incidence and Mortality, 2012 and 2035
Figure 2 : Common Types of Cancers in U.S., Estimated New Cases, 2013
Figure 3 : Colorectal Cancer Incidence Estimates in U.S., 2012-2022
Figure 4 : Colon and Rectal Cancer Incidence Estimates in U.S., 2013-2022
Figure 5 : Prostate Cancer Incidence and Mortality Worldwide, 2012
Figure 6 : Global Estimated Prostate Cancer Deaths: Age-Standardized Mortality Rates per 100,000 Men, 2012
Figure 7 : Global Estimated New Cases of Prostate Cancer, 2012-2022
Figure 8 : New Cases and Deaths of Prostate Cancer in U.S., 2012-2016
Figure 9 : Estimated Prostate Cancer Cases in U.S., 2020 and 2030
Figure 10 : Prostate Cancer Deaths in U.K.: Rate per 100,000 People, 2014
Figure 11 : Global Cancer Incidence – Estimates, 2008-2030
Figure 12 : Global Cancer Survivors, 2008
Figure 13 : Global Cancer Drug Market, 2013-2022
Figure 14 : Global In Vitro Diagnostics Market, 2012-2022
Figure 15 : Global Cancer Biomarkers Market, 2012-2022
Figure 16 : Global Molecular Diagnostics Market, 2012–2022
Figure 17 : Global Circulating Tumor Cell Testing Market, by Region, 2012–2022
Figure 18 : Global Circulating Tumor Cells for Prostate Cancer Market, by Region, 2012–2022
Figure 19 : Global Circulating Tumor Cells for Breast Cancer Market, by Region, 2012–2022
Figure 20 : Global Circulating Tumor Cells for Colorectal Cancer Market, by Region, 2012–2022
Figure 21 : U.S. Circulating Tumor Cells for Prostate Cancer Market, 2012–2022
Figure 22 : U.S. Circulating Tumor Cells Market, by Cancer Type, 2012-2022
Figure 23 : European Circulating Tumor Cells Market, 2012–2022
Figure 24 : European Circulating Tumor Cells Market, by Cancer Type, 2012-2022
Figure 25 : Rest of World Circulating Tumor Cells Market, 2012–2022
Figure 26 : Rest of World Circulating Tumor Cells Market, by Cancer Type, 2012-2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report